本文選題：健脾理濕益氣養(yǎng)陰方　切入點(diǎn)：多囊卵巢綜合征　出處：《黑龍江省中醫(yī)藥科學(xué)院》2016年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:旨在觀察健脾利濕益氣養(yǎng)陰方對(duì)多囊卵巢伴有胰島素抵抗的病患內(nèi)分泌、代謝、排卵情況等影響,探討其治療多囊卵巢綜合征伴有胰島素抵抗療效機(jī)理。方法:臨床研究采用對(duì)照和隨機(jī)的研究方法,將符合多囊卵巢綜合征伴有胰島素抵抗的病患,按1:1對(duì)照的原則,隨機(jī)分為治療組與對(duì)照組。在基礎(chǔ)治療之上,治療組給予中藥配方顆粒每日1劑,分早晚兩次飯后服用;對(duì)照組給予二甲雙胍500mg,每天2次,飯后服用。以1個(gè)月經(jīng)周期為1個(gè)療程,連續(xù)觀察3個(gè)療程。兩組在治療前后分別評(píng)價(jià)多囊卵巢伴有胰島素抵抗的臨床癥狀、其體征變化及實(shí)驗(yàn)室指標(biāo)。全部數(shù)據(jù)都以SPSS16.0統(tǒng)計(jì)軟件進(jìn)行統(tǒng)計(jì)學(xué)的分析。結(jié)果:1.臨床療效方面:治療組總有效率為93.33%。對(duì)照組總有效率為73.33%。治療組優(yōu)于對(duì)照組(P0.05)。2.中醫(yī)癥候方面:治療組癥候積分療后較療前明顯下降(P0.01);對(duì)照組癥候積分較治療前無(wú)明顯改變(P0.05),治療組優(yōu)于對(duì)照組(P0.01),療后三個(gè)月治療組優(yōu)于對(duì)照組(P0.01)。3.臨床癥狀及體征方面:(1)治療后兩組患者月經(jīng)情況均有改善(P0.01),治療組優(yōu)于對(duì)照組(P0.05),療后三個(gè)月月經(jīng)改善穩(wěn)定情況治療組優(yōu)于對(duì)照組(P0.05)。(2)治療后兩組患者BMI較治療前均有所下降(P0.01),治療組優(yōu)于對(duì)照組(P0.05),療后三個(gè)月治療組優(yōu)于對(duì)照組(P0.01)。(3)療后、療后三個(gè)月治療組患者多毛情況、痤瘡較治療前有所改善(P0.01),對(duì)照組改善情況不明顯(P0.05),治療組優(yōu)于對(duì)照組(P0.01)。(4)治療后兩組患者黑棘皮情況均有改善(P0.01),兩組改善程度無(wú)差異(P0.05),療后三個(gè)月治療組優(yōu)于對(duì)照組(P0.01)。4.性激素水平方面:(1)治療后兩組患者的T值均較治療前有所下降(P0.05),治療組雄激素下降程度優(yōu)于對(duì)照組(P0.05)。(2)治療后兩組患者LH值、LH/FSH值較治療前均有所下降(P0.01),且治療組下降程度優(yōu)于對(duì)照組(P0.05)。(3)治療前后兩組患者FSH值、E2值無(wú)明顯差異(P0.05)。5.胰島素相關(guān)指標(biāo)方面:治療后兩組患者FINS值、ISI值較治療前均有改善(P0.05),治療組改善程度與對(duì)照組無(wú)差異(P0.05)。治療前后兩組患者FPG無(wú)明顯差異。6.彩超影像學(xué)方面:治療后兩組患者竇卵泡數(shù)目較治療前有所下降(P0.05),且治療組竇卵泡數(shù)減少量?jī)?yōu)于對(duì)照組(P0.05)。7.排卵情況(基礎(chǔ)體溫測(cè)定)方面:療后、療后三個(gè)月兩組患者基礎(chǔ)體溫雙相率分別為40%、16.67%、33.33%、10%,治療組效果優(yōu)于對(duì)照組(P0.05)。8.安全性指標(biāo)方面:治療前后兩組患者血、尿、便常規(guī)及肝、腎功能均在正常范圍之內(nèi)。兩組均未見明顯不良反應(yīng)。結(jié)論:1.健脾利濕益氣養(yǎng)陰方結(jié)合基礎(chǔ)治療可改善胰島素抵抗(主要為降低FINS)。治療效果與二甲雙胍結(jié)合基礎(chǔ)治療相當(dāng)。2.健脾利濕益氣養(yǎng)陰方結(jié)合基礎(chǔ)治療可顯著改善多囊卵巢綜合征癥候群,且療后三個(gè)月復(fù)發(fā)率低。治療效果優(yōu)于二甲雙胍結(jié)合基礎(chǔ)治療。
[Abstract]:Objective: to observe the effects of invigorating spleen, dampness and supplementing qi and nourishing yin on endocrine, metabolism and ovulation in patients with polycystic ovary accompanied by insulin resistance. Methods: control and randomized methods were used to treat patients with polycystic ovary syndrome with insulin resistance according to the principle of 1: 1 control. The treatment group was divided into treatment group and control group at random. On the basis of basic treatment, the treatment group was given 1 dose of traditional Chinese medicine prescription granule daily, taken after two meals in the morning and evening, while the control group was given metformin 500 mg twice a day, One menstrual cycle was used as a course of treatment, and three consecutive courses of treatment were observed. The clinical symptoms of polycystic ovary with insulin resistance were evaluated before and after treatment. All the data were analyzed statistically by SPSS16.0 software. Results: 1. Clinical efficacy: the total effective rate of the treatment group was 93.33. The total effective rate of the control group was 73.33. The treatment group was superior to the control group (P0.05. 2). The symptom score of the treatment group was significantly lower than that of the control group after treatment, while that of the control group had no significant change compared with that before treatment, the treatment group was superior to the control group, and the treatment group was superior to the control group three months after treatment. The clinical symptoms and signs of the treatment group were better than that of the control group. (1) after treatment, the menstrual status of the two groups was improved, the treatment group was superior to the control group (P 0.05), the treatment group was superior to the control group in improving menstrual stability three months after treatment, and the control group was superior to the control group (P 0.05). After treatment, the BMI of the two groups was lower than that of the control group (P 0.01), and the treatment group was better than that of the control group (P 0.01). The treatment group was superior to the control group (P 0.05), and the treatment group was superior to the control group (P 0.01) three months after treatment. Three months after treatment, the patients in the treatment group suffered from hirsutism. The acnes in the treatment group was better than that in the control group (P 0.01). There was no difference in the degree of improvement between the two groups. The treatment group was superior to the control group in three months after treatment, and the treatment group was superior to the control group. After the treatment, the T value of the two groups was lower than that before treatment. The decrease of androgen in the treatment group was better than that in the control group (P 0.05. 0. 2) after treatment, the LH value and the LH / FSH value of the two groups were lower than those before treatment, and the treatment group had a decrease in the value of LHP / FSH, and the treatment group had a lower value of LH / FSH than that of the control group (P < 0. 05, P < 0. 05, P < 0. 05). Before and after treatment, there was no significant difference in FSH value and E2 value between the two groups. Insulin related indexes: after treatment, the FINS value of the two groups was improved compared with that of the control group (P 0.05), and the improvement degree of the treatment group was higher than that of the control group. There was no significant difference in FPG between the two groups before and after treatment. 6. Color Doppler Imaging: the number of antral follicles in the two groups was lower than that before treatment, and the number of antral follicles in the treatment group was lower than that in the control group. Basic body temperature measurement): after treatment, Three months after treatment, the biphasic rates of basic body temperature in the two groups were 40 ~ 16.67 ~ 33.33 and 10, respectively. The effect of the treatment group was better than that of the control group (P 0.05) .8. the safety indexes were as follows: before and after treatment, the patients in the two groups had blood, urine, stool routine and liver. The renal function was within normal range. There were no obvious adverse reactions in the two groups. Conclusion 1. The combination of tonifying spleen, dampness and supplementing qi and nourishing yin can improve insulin resistance (mainly reducing FINSN). The therapeutic effect is based on metformin. 2. The combination of invigorating spleen, dampness and supplementing qi and nourishing yin can significantly improve the syndrome of polycystic ovary syndrome. The recurrence rate was low 3 months after treatment and the therapeutic effect was better than metformin combined with basic treatment.
【學(xué)位授予單位】：黑龍江省中醫(yī)藥科學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R271.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 郭文;羅素明;魏可新;李景云;;用于校準(zhǔn)~(192)Ir醫(yī)用源的阱型電離室[J];原子能科學(xué)技術(shù);2007年01期

2 陳明,劉兆平,王日勝,霍勇;~(192)Ir血管內(nèi)照射防止兔球囊血管成形術(shù)后再狹窄[J];中國(guó)介入心臟病學(xué)雜志;2000年03期

3 陳明,霍勇,劉兆平,王日勝,朱國(guó)英;~(192)Ir血管內(nèi)照射防止兔球囊血管成形術(shù)后再狹窄[J];Chinese Medical Journal;2001年01期

4 聶波;張貴君;孫素琴;周群;丁萬(wàn)隆;;不同金蓮花藥材的IR鑒別研究[J];中藥材;2006年04期

5 白震民;原一;唐強(qiáng);陳世龍;;針刺對(duì)IR模型大鼠胰島素敏感性的影響[J];針灸臨床雜志;2007年08期

6 張旭光,山常起,馬旺扣,吳翼偉,王棟梁;~(192)Ir顆粒源的制造和輻射劑量檢測(cè)[J];中華核醫(yī)學(xué)雜志;2004年02期

7 田宜清,王曉霞;一例~(192)Ir源放射事故調(diào)查處理報(bào)告[J];職業(yè)與健康;2001年07期

8 王進(jìn);楊春勇;余寧樂;許翠珍;杜翔;張乙眉;;江蘇省后裝近距離治療機(jī)~(192)Ir放射源有效活度檢測(cè)與分析[J];輻射防護(hù);2009年04期

9 張紅志，殷蔚伯，馮寧遠(yuǎn)，，余子豪;近距離治療中~(192)Ir放射源的校準(zhǔn)[J];中華放射腫瘤學(xué)雜志;1997年01期

10 欽志泉,張?zhí)K展,盧麗琴,劉子江,賈勇士,吳樹強(qiáng);~(192)Ir內(nèi)放療增加肺癌動(dòng)脈化療和外照射療效的臨床研究[J];腫瘤防治雜志;2003年01期

相關(guān)會(huì)議論文 前10條

1 劉羽;劉翠;梁良;黃瀾;朱華;許艷峰;秦川;;小鼠腦部SIRT1與IRα受體的共定位及分布[A];第十屆中國(guó)實(shí)驗(yàn)動(dòng)物科學(xué)年會(huì)論文集[C];2012年

2 陳貽竹;Murchie EH;Peng SB;Horton P;;水稻IR系列品種的光合作用和葉綠素?zé)晒獾奶匦訹A];全國(guó)植物光合作用、光生物學(xué)及其相關(guān)的分子生物學(xué)學(xué)術(shù)研討會(huì)論文摘要匯編[C];2001年

3 廖勇;馬弘舸;楊周炳;李科;謝平;孟凡寶;;4.5m拋物面沖擊脈沖天線(IR)實(shí)驗(yàn)[A];中國(guó)工程物理研究院科技年報(bào)（2003）[C];2003年

4 ;降低彩電MT822機(jī)芯IR板產(chǎn)品不良率[A];QCC—開發(fā)潛能 和諧提升——2010年度電子信息行業(yè)優(yōu)秀質(zhì)量管理小組成果、質(zhì)量信得過班組經(jīng)驗(yàn)專集[C];2010年

5 寧建華;;電鑄成型的Ir／Re火箭發(fā)動(dòng)機(jī)燃燒室[A];2001年中國(guó)機(jī)械工程學(xué)會(huì)年會(huì)暨第九屆全國(guó)特種加工學(xué)術(shù)年會(huì)論文集[C];2001年

6 陳改榮;楊書廷;呂慶章;鄭洪河;趙林治;張明春;丁立;;Na_2SO_4-Na_2MoO_4體系的相關(guān)系IR譜分析與導(dǎo)電機(jī)理研究[A];第三屆中國(guó)功能材料及其應(yīng)用學(xué)術(shù)會(huì)議論文集[C];1998年

7 韓益蘋;羅鵬;蔡稱心;陸天虹;;Ir催化劑中Ir粒子平均粒徑對(duì)氨氧化的電催化性能的影響[A];中國(guó)化學(xué)會(huì)第26屆學(xué)術(shù)年會(huì)分析化學(xué)分會(huì)場(chǎng)論文集[C];2008年

8 孔慶梅;韓益蘋;陸天虹;唐亞文;;炭載Ir催化劑對(duì)氨氧化的電催化性能[A];中國(guó)化學(xué)會(huì)第26屆學(xué)術(shù)年會(huì)分析化學(xué)分會(huì)場(chǎng)論文集[C];2008年

9 張保才;蔡偉杰;徐奕德;申文杰;;Ir／CeO_2催化劑上乙醇水蒸氣重整制氫反應(yīng)的研究[A];第十三屆全國(guó)催化學(xué)術(shù)會(huì)議論文集[C];2006年

10 南征;;消渴難治證—胰島素抵抗(IR)淺論[A];第九次全國(guó)中醫(yī)糖尿病學(xué)術(shù)大會(huì)論文匯編[C];2006年

相關(guān)重要報(bào)紙文章 前9條

1 宜眾通達(dá) 楊麗丹;第一食品 追求IR和諧境界[N];上海證券報(bào);2005年

2 記者 孫哲;近七成上市公司沒有IR長(zhǎng)期規(guī)劃[N];北京商報(bào);2013年

3 唐坤;IR顧問遭遇股改挑戰(zhàn)[N];上海證券報(bào);2005年

4 李月梅;全球首款I(lǐng)R智能現(xiàn)實(shí)明信片在廣東肇慶首發(fā)[N];中國(guó)郵政報(bào);2012年

5 博星投資 袁光順;低投票率挑戰(zhàn)股改IR成效[N];上海證券報(bào);2005年

6 記者崔毅羅威;東風(fēng)汽車:IR制度化就是我的第六感女神[N];中國(guó)經(jīng)營(yíng)報(bào);2003年

7 上海潤(rùn)言投資咨詢有限公司;股權(quán)分置改革催生IR經(jīng)典戰(zhàn)役[N];上海證券報(bào);2005年

8 本報(bào)記者 李軒;IR公司繼續(xù)擴(kuò)大在華投資[N];計(jì)算機(jī)世界;2002年

9 夏麗華;避免股改后IR管理誤區(qū)[N];中國(guó)證券報(bào);2007年

相關(guān)博士學(xué)位論文 前2條

1 陳東初;Ir、W金屬/金屬氧化物H~+選擇性電極的研究[D];華中科技大學(xué);2004年

2 何朝政;NH_3和NO在金屬Ir表面吸附與解離的第一性原理研究[D];吉林大學(xué);2013年

相關(guān)碩士學(xué)位論文 前10條

1 唐國(guó)棟;氧化—還原中性條件下Ir(Ⅲ)和Rh(Ⅲ)催化芳烴碳?xì)滏I活化及其官能化[D];安徽理工大學(xué);2016年

2 宋詞;健脾利濕益氣養(yǎng)陰方治療PCOS伴IR的臨床觀察[D];黑龍江省中醫(yī)藥科學(xué)院;2016年

3 陳世龍;針刺對(duì)喂養(yǎng)型IR大鼠GLUT4、IRS1影響的研究[D];黑龍江中醫(yī)藥大學(xué);2008年

4 陳曉寧;IR集團(tuán)公司產(chǎn)品創(chuàng)新管理體系優(yōu)化研究[D];西北大學(xué);2006年

5 郁明珠;Ir催化劑對(duì)氨氧化的電催化性能的研究[D];南京師范大學(xué);2013年

6 楊倫權(quán);Ir納米粒子的形貌控制及其催化性能研究[D];昆明理工大學(xué);2012年

7 孫麗君;含有酰胺輔助配體的Ir（Ⅲ）配合物的合成及發(fā)光性質(zhì)的研究[D];江南大學(xué);2013年

8 馬麗花;強(qiáng)可見光吸收、長(zhǎng)壽命三重激發(fā)態(tài)Ir~Ⅲ配合物的合成及應(yīng)用[D];大連理工大學(xué);2013年

9 鄭淑紅;T2DM早期血管內(nèi)皮舒張功能的變化及其與SF、ox-LDL、IR的相關(guān)性研究[D];第三軍醫(yī)大學(xué);2010年

10 衣秀羽;強(qiáng)可見光吸收的Ir（Ⅲ）、Re（Ⅰ）配合物的合成與應(yīng)用研究[D];大連理工大學(xué);2013年

本文編號(hào)：1634074